Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007-001 Studies.

Michael C Heinrich Xinhua Zhang Robin L Jones Suzanne George Cesar Serrano Yan-Hong Deng Sebastian Bauer Shirong Cai Xin Wu Yongjian Zhou Kaixiong Tao Zhi-Chao Zheng Jun Zhang Yuehong Cui Hui Cao Meining Wang Jin Hu Jason Yang Jian Li Lin Shen

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Avapritinib showed greater antitumor activity in patients with GISTs harboring KIT ALposABPneg mutations versus KIT OTHERS, and may be considered in the former subpopulation. Patients with KIT exon 9 mutations may also benefit in ³4 line settings.

Keyphrases